References
- Salloum IM, Brown ES. Management of comorbid bipolar disorder and substance use disorders. AJDAA 2017;43:366–376.
- Bennett ME, Bradshaw KR, Catalano LT. Treatment of substance use disorders in schizophrenia. AJDAA 2017;43:377–390.
- Taylor M, Petrakis I, Ralevski E. Treatment of alcohol use disorder and co-occurring PTSD. AJDAA 2017;43:391–401.
- Salloum IM, Cornelius JR, Daley DC, Kirisci L, Himmelhoch JM, Thase ME. Efficacy of valproate maintenance in patients with bipolar disorder and alcoholism: a double-blind placebo-controlled study. Arch Gen Psychiatry 2005;62:37–45.
- Brown ES, Todd JP, Hu LT, Schmitz JM, Carmody TJ, Nakamura A, Sunderajan P, Rush AJ, Adinoff B, Bret ME, Holmes T, Lo A. A randomized, double-blind, placebo-controlled trial of citicoline for cocaine dependence in bipolar I disorder. Am J Psychiatry 2015;172:1014–1021.
- Vujanovic AA, Meyer TD, Heads AM, Stotts AL, Villarreal YR, Schmitz JM. Cognitive-behavioral therapies for depression and substance use disorders: an overview of traditional, third-wave, and transdiagnostic approaches. AJDAA 2017;43:402–415.
- Weinberger AH, Kasham RS, Shpigel DM, Esan H, Taha F, Lee CJ, Funk AP, Goodwin RD. Depression and cigarette smoking behavior: a critical review of population-based studies. AJDAA 2017;43:416–431.
- Keyser-Marcus L, Vassileva J, Stewart K, Johns S. Impulsivity and cue reactivity in smokers with comorbid depression and anxiety: possible implications for smoking cessation treatment strategies. AJDAA 2017;43:432–441.
- Hanna RC, Perez JM, Ghose S. Cannabis and development of dual diagnoses: a literature review. AJDAA 2017;43:442–455.
- Ng E, Browne CJ, Samsom JN, Wong AH. Depression and substance use comorbidity: what we have learned from animal studies. AJDAA 2017;43:456–474.
- Peters RH, Young MS, Rojas EC, Gorey CM. Evidence-based treatment and supervision practices for co-occurring mental and substance use disorders in the criminal justice system. AJDAA 2017;43:475–488.